Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

1996 • 1,281 citations

Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule

1994 • 1,120 citations

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

1996 • 1,001 citations

Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

1993 • 643 citations

Fas and FasL in the homeostatic regulation of immune responses

1995 • 579 citations

Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing.

1995 • 398 citations

The host—tumor immune conflict: from immunosuppression to resistance and destruction

1997 • 363 citations

Fas and Fas Ligand: A Death Factor and Its Receptor

1994 • 354 citations

Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity

1997 • 284 citations

Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness.

1994 • 262 citations

The Fas counterattack: cancer as a site of immune privilege

1999 • 240 citations

Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis

1998 • 164 citations

Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias

1995 • 148 citations

Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.

1996 • 142 citations

Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?

1995 • 110 citations

Resistance to CD95/Fas‐induced and ceramide‐mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release

2000 • 98 citations

Biologically Active Fas Antigen and Its Cognate Ligand Are Expressed on Plasma Membrane-Derived Extracellular Vesicles

1998 • 98 citations

Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases

1997 • 96 citations

PROGNOSTIC SIGNIFICANCE OF SOLUBLE FAS IN THE SERUM OF PATIENTS WITH BLADDER CANCER

1998 • 89 citations

Circulating soluble Fas concentration in breast cancer patients.

1999 • 86 citations

Human Melanoma-Reactive CD4+ and CD8+ CTL Clones Resist Fas Ligand-Induced Apoptosis and Use Fas/Fas Ligand-Independent Mechanisms for Tumor Killing

1998 • 83 citations

Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma

1998 • 82 citations

Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-?

1999 • 62 citations

CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95)

1998 • 52 citations

Serum soluble fas levels in ovarian cancer

2000 • 47 citations

Soluble Fas in serum from patients with renal cell carcinoma

2000 • 40 citations

A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin’s lymphoma

1999 • 33 citations

Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines

1997 • 30 citations

Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes.

1996 • 28 citations

Signaling Events in T Lymphocytes Leading to Cellular Activation or Programmed Cell Death

1997 • 27 citations

Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients

1999 • 25 citations

Soluble CD95 in the Serum of Patients with Low and Intermediate Grade Malignant Lymphomas: Absence of Prognostic Correlations

1997 • 11 citations

Serum soluble Fas/APO-1 is increased in patients with primary Sj�gren's syndrome

1998 • 11 citations

Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?

1998 • 10 citations